Advaccine is an innovative vaccine company that has developed a high-value prophylactic and therapeutic vaccine pipeline based on mature in-house technology platforms and possesses commercial manufacturing capabilities. Advaccine's key pipeline in development includes potential innovative vaccines targeting diseases caused by SARS-CoV-2, respiratory syncytial virus (RSV), and hepatitis B virus (HBV), all of which are diseases with significantly unmet medical needs. Advaccine is also developing a series of cancer vaccine candidates, including vaccine candidates for virus-related tumors, neoantigen-based therapeutic vaccines, and tumor-associated antigen (TAA) therapeutic vaccines. Advaccine is an innovative vaccine company with a high-value prophylactic and therapeutic vaccine pipeline driven by in-house developed technology platforms and industrial manufacturing capabilities. Its pipeline consists of potential first-in- key assets developed to address diseases caused by SARS-CoV-2, respiratory syncytial virus (RSV) and hepatitis B virus (HBV), which are diseases with huge unmet medical needs. Advaccine is also developing a series of cancer vaccine candidates, covering viral-related oncology, neoantigen-based therapeutic vaccines and tumor-associated antigen therapeutic vaccines.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows